Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib dose-ranging study in adults with peanut allergy
2021-006950-30Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of remibrutinib in peanut allergy (2 arms), sponsored by Novartis. Primary endpoint: Responder status at one month for tolerance of at least 600 mg single peanut protein dose. Started Jun 2022; status: terminated.
02
Drugs
remibrutinib
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2021-006950-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006950-30.